Navigation Links
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
Date:10/12/2010

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charit University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.

Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine system. These cells are found throughout the body in organs such as the gastrointestinal tract and the lungs. The tumors are mostly non-responsive to chemotherapy drugs. They affect less than five people in 100,000, and until now there have been few treatment options for inhibition of tumor growth.

In the new RADIANT-2 trial, researchers in several European countries and the USA treated 429 patients with progressing, well- or moderately-differentiated advanced neuroendocrine tumors with either everolimus plus a somatostatin analog called octreotide LAR, or placebo plus octreotide LAR.

All patients had a history of 'carcinoid' symptoms, meaning the tumors have been secreting excessive levels of amines, especially serotonin, leading to symptoms such as flushing and diarrhea. The tumor originated in the small intestine in about 50% of patients.

Overall, the median progression-free survival for patients given everolimus plus octreotide LAR was 16.4 months, significantly longer than the median 11.3 months for placebo plus octreotide LAR, Dr Pavel reported.

"This is the first Phase-III trial of the combination therapy with octreotide LAR and everolimus and it is the largest trial that has ever been done in this type of neuroendocrine tumors," Dr Pavel said. "When we designed the study, we tested for an improvement of at least 4.5 months compared to octreotide LAR and were pleased with the resulting 5.1 month difference."

Currently, treatment options for neuroendocrine tumors are limited. Chemotherapy is only effective in neuroendocrine tumors affecting the pancreas. For tumors that originate in other organs, treatments include somatostatin analogs that control symptoms related to over-secretion of compounds such as serotonin. Interferon-alpha is also approved for these types of neuroendocrine tumors which are also referred to as carcinoid tumors. A placebo-controlled trial recently demonstrated that octreotide LAR has anti-tumor effects in neuroendocrine tumors of the small intestine.

"Since chemotherapeutic drugs are not effective in this type of neuroendocrine tumor patient, we now have for the first time a drug that has been studied in a Phase-III trial that offers antitumor efficacy in addition to the currently available agents, somatostatin analogs and interferon," Dr Pavel said.

"I think the drug will be further explored in this type of tumor. It seems important to identify patients that may benefit most from the combination of everolimus and octreotide LAR compared to octreotide LAR alone."

Dr Roberto Labianca from Ospedali Riuniti di Bergamo, Italy, commented: "This large Phase III trial in a rare tumor shows that everolimus is able to increase the efficacy of octreotide LAR, at the present time the standard treatment for advanced neuroendocrine tumors."

"This trial should be considered a practice-changing achievement but it is essential that selection criteria are refined in order to identify the population more likely to respond to this approach," Dr Labianca said. "Further trials in this field are needed, preferably in the frame of a large cooperative collaboration."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Front-of-package symbols and systems: IOM phase 1 report
2. Vaccine extends glioblastoma patients survival in phase II trial
3. Operation Unified Response: 3 phases of disaster care in Haiti
4. Aeras and Crucell announce Phase II clinical trial start in Kenya
5. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
6. Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial
7. Late-stage ovarian cancer shows promise in 2-drug phase I trial
8. Late-stage ovarian cancer shows promise in two-drug phase I trial
9. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... Minneapolis MN (PRWEB) , ... February 23, 2017 , ... ... it is sending an expert sit stand solutions representative to the Minneapolis Home and ... 5. Location for the event that is garnering national attention is the Minneapolis Convention ...
(Date:2/22/2017)... FL (PRWEB) , ... February 22, 2017 , ... Gevir, ... from deer antler velvet, announced its products are coming soon to Amazon.com, the world’s ... and Shelley Thomson as a means to develop an effective natural treatment for Shelley’s ...
(Date:2/22/2017)... ... ... South Bend’s Lunkerville, the award-winning TV series that catches real people with ... a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through kayak ... Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the New ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology: